BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26432605)

  • 1. 5-Lipoxygenase inhibitors suppress RANKL-induced osteoclast formation via NFATc1 expression.
    Kang JH; Ting Z; Moon MR; Sim JS; Lee JM; Doh KE; Hong S; Cui M; Choi S; Chang HW; Park Choo HY; Yim M
    Bioorg Med Chem; 2015 Nov; 23(21):7069-78. PubMed ID: 26432605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Lipoxygenase mediates RANKL-induced osteoclast formation via the cysteinyl leukotriene receptor 1.
    Lee JM; Park H; Noh AL; Kang JH; Chen L; Zheng T; Lee J; Ji SY; Jang CY; Shin CS; Ha H; Lee ZH; Park HY; Lee DS; Yim M
    J Immunol; 2012 Dec; 189(11):5284-92. PubMed ID: 23109727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
    Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
    BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
    Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.
    Kim HJ; Yoon KA; Lee MK; Kim SH; Lee IK; Kim SY
    Life Sci; 2012 Nov; 91(19-20):928-34. PubMed ID: 23000100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orostachys japonicus Suppresses Osteoclast Differentiation by Inhibiting NFATc1 Expression.
    Shim KS; Ha H; Kim T; Lee CJ; Ma JY
    Am J Chin Med; 2015; 43(5):1013-30. PubMed ID: 26205967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminocoumarins inhibit osteoclast differentiation and bone resorption via downregulation of nuclear factor of activated T cells c1.
    Zheng T; Noh AL; Park H; Yim M
    Biochem Pharmacol; 2013 Feb; 85(3):417-25. PubMed ID: 23123663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice.
    Kim JY; Cheon YH; Oh HM; Rho MC; Erkhembaatar M; Kim MS; Lee CH; Kim JJ; Choi MK; Yoon KH; Lee MS; Oh J
    Bone; 2014 Mar; 60():104-11. PubMed ID: 24361669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
    Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
    Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption.
    Park CK; Kim HJ; Kwak HB; Lee TH; Bang MH; Kim CM; Lee Y; Chung DK; Baek NI; Kim J; Lee ZH; Kim HH
    Int Immunopharmacol; 2007 Dec; 7(12):1507-16. PubMed ID: 17920527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades.
    Song F; Wei C; Zhou L; Qin A; Yang M; Tickner J; Huang Y; Zhao J; Xu J
    J Cell Physiol; 2018 Feb; 233(2):1723-1735. PubMed ID: 28681916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Miconazole inhibits receptor activator of nuclear factor-κB ligand-mediated osteoclast formation and function.
    Zheng T; Wang X; Yim M
    Eur J Pharmacol; 2014 Aug; 737():185-93. PubMed ID: 24842191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhinacanthin C Inhibits Osteoclast Differentiation and Bone Resorption: Roles of TRAF6/TAK1/MAPKs/NF-κB/NFATc1 Signaling.
    Tomomura M; Suzuki R; Shirataki Y; Sakagami H; Tamura N; Tomomura A
    PLoS One; 2015; 10(6):e0130174. PubMed ID: 26083531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
    He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
    Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.